Browsing Tag
HR+/HER2- breast cancer
2 posts
Celcuity moves gedatolisib toward U.S. approval with NDA filing for HR+/HER2- advanced breast cancer patients
Discover how Celcuity’s FDA review for gedatolisib could expand treatment choices for HR+/HER2- PIK3CA wild-type advanced breast cancer patients.
Kelun-Biotech reports strong Phase 3 data for sacituzumab tirumotecan in HR+/HER2- breast cancer
Kelun-Biotech’s sacituzumab tirumotecan doubled PFS in HR+/HER2- breast cancer. Find out what this means for patients, investors, and China’s ADC landscape.